SOHM, Inc. Announce Dr. Wei Zhu Onboard as Senior Marketing and Sales Consultant
SOHM Inc. (OTC PINK:SHMN) has appointed Dr. Wei Zhu as Senior Marketing and Sales Consultant for its biotech ABBIE division. Dr. Zhu brings over 20 years of experience in Molecular and Cellular Biology, Biochemistry, Immunology, Signal Transduction, Cancer Biology, and Developmental Biology. Her expertise includes advanced Bioinformatics, Sequence-based Genomics Research, Histology, and animal model work. The appointment is effective immediately, and she will contribute to the company's marketing and sales efforts in pharmaceutical, cosmeceutical, and nutraceutical products.
SOHM Inc. (OTC PINK:SHMN) ha nominato Dr. Wei Zhu come Consulente Senior di Marketing e Vendite per la sua divisione biotech ABBIE. La Dr. Zhu porta con sé oltre 20 anni di esperienza in Biologia Molecolare e Cellulare, Biochimica, Immunologia, Trasduzione del Segnale, Biologia del Cancro e Biologia dello Sviluppo. La sua esperienza include Bioinformatica avanzata, Ricerca Genomica basata su Sequenze, Istologia e lavori su modelli animali. La nomina è effettiva immediatamente e contribuirà agli sforzi di marketing e vendita dell'azienda nel settore dei prodotti farmaceutici, cosmetici e nutraceutici.
SOHM Inc. (OTC PINK:SHMN) ha nombrado a Dr. Wei Zhu como Consultora Senior de Marketing y Ventas para su división biotecnológica ABBIE. La Dra. Zhu aporta más de 20 años de experiencia en Biología Molecular y Celular, Bioquímica, Inmunología, Transducción de Señales, Biología del Cáncer y Biología del Desarrollo. Su experiencia incluye Bioinformática avanzada, Investigación Genómica basada en Secuencias, Histología y trabajo con modelos animales. El nombramiento es efectivo inmediatamente y contribuirá a los esfuerzos de marketing y ventas de la empresa en productos farmacéuticos, cosmeceuticos y nutracéuticos.
SOHM Inc. (OTC PINK:SHMN)이 Dr. Wei Zhu를 자회사 ABBIE의 수석 마케팅 및 판매 컨설턴트로 임명했습니다. Zhu 박사는 분자 및 세포 생물학, 생화학, 면역학, 신호 전달, 암 생물학 및 발달 생물학에서 20년 이상의 경험을 가지고 있습니다. 그녀의 전문 분야에는 고급 생물정보학, 서열 기반 유전체 연구, 조직학, 동물 모델 작업이 포함됩니다. 이 임명은 즉시 효력이 있으며, 제약, 코스메슈티컬 및 영양 보충제 제품의 마케팅 및 판매 노력을 지원할 것입니다.
SOHM Inc. (OTC PINK:SHMN) a nommé Dr. Wei Zhu en tant que Consultante Senior en Marketing et Vente pour sa division biotechnologique ABBIE. Le Dr. Zhu apporte plus de 20 ans d'expérience en Biologie Moléculaire et Cellulaire, Biochimie, Immunologie, Transduction du Signal, Biologie du Cancer et Biologie du Développement. Son expertise comprend la Bioinformatique avancée, la Recherche Génomique basée sur des Séquences, l'Histologie et le travail sur des modèles animaux. La nomination prend effet immédiatement et elle contribuera aux efforts de marketing et de vente de l'entreprise dans les produits pharmaceutiques, cosmétiques et nutraceutiques.
SOHM Inc. (OTC PINK:SHMN) hat Dr. Wei Zhu zur Senior Marketing- und Verkaufsberaterin für die Biotech-Abteilung ABBIE ernannt. Dr. Zhu bringt über 20 Jahre Erfahrung in Molekular- und Zellbiologie, Biochemie, Immunologie, Signaltransduktion, Krebsbiologie und Entwicklungsbiologie mit. Ihr Fachwissen umfasst fortgeschrittene Bioinformatik, sequenzbasierte Genomforschung, Histologie und Arbeiten mit Tiermodellen. Die Ernennung tritt sofort in Kraft und sie wird zu den Marketing- und Verkaufsaktivitäten des Unternehmens im Bereich pharmazeutischer, kosmetischer und nutraceutical Produkte beitragen.
- Appointment of experienced scientific professional with 20+ years expertise in multiple biotechnology fields
- Strategic addition to strengthen marketing and sales capabilities in biotech division
- None.
CHINO HILLS, CA / ACCESSWIRE / November 20, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has appointed Dr. Wei Zhu as its Senior Marketing and Sales Consultant for its biotech ABBIE division.
Mr. Baron Night, CEO of SOHM Inc., is pleased to announce the appointment of Dr. Wei Zhu as the company's Senior Marketing and Sales Consultant, effective immediately.
Dr. Zhu brings over 20 years of distinguished experience across Molecular and Cellular Biology, Biochemistry, Immunology, Signal Transduction, Cancer Biology, and Developmental Biology.
Dr. Zhu is well-recognized in the scientific community for a hands-on approach to scientific research, combined with a passion for innovation and extensive expertise in technical and strategic domains. Known for her problem-solving skills and commitment to collaboration, she excels in building bridges within and beyond scientific communities, making her an asset to both her peers and SOHM's growing team.
Dr. Zhu's technical skill set spans a broad range of high-impact areas, including Molecular Biology, Biochemistry, and Signal Transduction. Her experience also encompasses advanced Bioinformatics and Sequence-based Genomics Research, along with Histology and animal model work, making her exceptionally well-rounded in life sciences research and development. Her expertise aligns with SOHM's ongoing commitment to pioneering advancements in pharmaceutical, cosmeceutical, and nutraceutical products.
Mr. Baron Night, CEO of SOHM Inc., commented, "We are excited to welcome Dr. Zhu to SOHM. Her exceptional track record, scientific acumen, and collaborative spirit will be invaluable in driving our marketing and sales efforts forward. We look forward to her contributions as we continue to expand our footprint in the life sciences market."
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.
To learn more about SOHM, Inc., visit www.SOHM.com.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on accesswire.com
FAQ
Who did SOHM Inc. (SHMN) appoint as Senior Marketing and Sales Consultant in November 2023?
What are Dr. Wei Zhu's areas of expertise joining SOHM Inc. (SHMN)?
What division will Dr. Wei Zhu be working with at SOHM Inc. (SHMN)?
